BACKGROUND: our research aim to study the role of AQP1 in the cardioprotective effect of remifentanil post-conditioning for myocardial ischemia/reperfusion injury. METHODS: Ninety Sprague-Dawley (SD) rats were divided into 6 groups: sham operation group (Sham group), myocardial ischemia and reperfusion group (I/R group), postconditioning of remifentanil group (R-post), postconditioning of remifentanil plus AQP1 inhibitor acetazolamide group (R-post +Ace), postconditioning of remifentanil plus opioid-receptor antagonist compounds (R-post +AC), postconditioning of remifentanil plus AQP1 enhancer arginine vasopressin (R-post +AV). All groups except the sham operation group were given 30 min ischemia in left anterior descending (LAD) coronary arteries. All groups were then given 120 min reperfusion to the LAD. Before reperfusion, the R-post, R-post +Ace, R-post +AC, R-post +AV groups were given 10 min remifentanil post-conditioning. Hemodynamic data were measured every 30 min after initiation of ischemia. The rats' hearts were exercised for detecting infarct size and water content in the left ventricle, and AQP1 expression were also detected. RESULTS: The R-post group showed a significant reduction of the infarct size compared to the I/R group. The effect of R-post for reducing infarct size was slightly enhanced by adding acetazolamide to R-post, so significant differences could still be found when compared R-post+Ace group to the I/R group. The effect of infarct size reduction brought by R-post was blocked by the opioid-receptor antagonist compounds. This effect was also blocked by the AQP1 enhancer. Similar outcomes were found considering the water content of the left ventricle and the AQP1 expression. CONCLUSION: Cardioprotective effect of remifentanil post-conditioning may initiate through inhibiting the function of AQP1.
BACKGROUND: our research aim to study the role of AQP1 in the cardioprotective effect of remifentanilpost-conditioning for myocardial ischemia/reperfusion injury. METHODS: Ninety Sprague-Dawley (SD) rats were divided into 6 groups: sham operation group (Sham group), myocardial ischemia and reperfusion group (I/R group), postconditioning of remifentanil group (R-post), postconditioning of remifentanil plus AQP1 inhibitor acetazolamide group (R-post +Ace), postconditioning of remifentanil plus opioid-receptor antagonist compounds (R-post +AC), postconditioning of remifentanil plus AQP1 enhancer arginine vasopressin (R-post +AV). All groups except the sham operation group were given 30 min ischemia in left anterior descending (LAD) coronary arteries. All groups were then given 120 min reperfusion to the LAD. Before reperfusion, the R-post, R-post +Ace, R-post +AC, R-post +AV groups were given 10 min remifentanilpost-conditioning. Hemodynamic data were measured every 30 min after initiation of ischemia. The rats' hearts were exercised for detecting infarct size and water content in the left ventricle, and AQP1 expression were also detected. RESULTS: The R-post group showed a significant reduction of the infarct size compared to the I/R group. The effect of R-post for reducing infarct size was slightly enhanced by adding acetazolamide to R-post, so significant differences could still be found when compared R-post+Ace group to the I/R group. The effect of infarct size reduction brought by R-post was blocked by the opioid-receptor antagonist compounds. This effect was also blocked by the AQP1 enhancer. Similar outcomes were found considering the water content of the left ventricle and the AQP1 expression. CONCLUSION: Cardioprotective effect of remifentanilpost-conditioning may initiate through inhibiting the function of AQP1.
Authors: Kook Jin Chun; Yong Hyun Park; Jeong Su Kim; Youngho Jang; June Hong Kim; Jun Kim; Mi Young Lee Journal: J Cardiothorac Vasc Anesth Date: 2011-04-22 Impact factor: 2.628
Authors: Amanda J Zatta; Hajime Kin; Darice Yoshishige; Rong Jiang; Ningping Wang; James G Reeves; James Mykytenko; Robert A Guyton; Zhi-Qing Zhao; James L Caffrey; Jakob Vinten-Johansen Journal: Am J Physiol Heart Circ Physiol Date: 2008-01-18 Impact factor: 4.733
Authors: Javier Inserte; David Garcia-Dorado; Victor Hernando; Ignasi Barba; Jordi Soler-Soler Journal: Cardiovasc Res Date: 2006-03-06 Impact factor: 10.787
Authors: Jonathan R Egan; Tanya L Butler; Andrew D Cole; Avetis Aharonyan; David Baines; Neil Street; Manchula Navaratnam; Oliver Biecker; Carla Zazulak; Carol G Au; Yee Mun Tan; Kathryn N North; David S Winlaw Journal: J Thorac Cardiovasc Surg Date: 2008-05-23 Impact factor: 5.209